Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darapladib in stable coronary heart disease
NCT00269048Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2005
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of darapladib in coronary heart disease (CHD) and atherosclerosis (4 arms), sponsored by GSK. Primary endpoint: On treatment sustained inhibition of plasma Lp-PLA2 activity at 12 weeks. Started Nov 2005; status: completed.
02
Drugs
darapladib
03
Conditions
coronary heart disease (CHD)atherosclerosis
Beyond the preview
Go deeper on NCT00269048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269048.